Vincerx Pharma, Inc. financial data

Symbol
VINC on Nasdaq
Industry
Pharmaceutical Preparations
Location
260 Sheridan Avenue, Suite 400, Palo Alto, CA
Fiscal year end
December 31
Former names
Vincera Pharma, Inc. (to 1/5/2021), LifeSci Acquisition Corp. (to 12/22/2020)
Latest financial report
10-K - Q4 2024 - Mar 27, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 165 % -49.9%
Debt-to-equity 108 % +123%
Return On Equity -451 % -140%
Return On Assets -217 % -71.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 5.23M shares -75.6%
Common Stock, Shares, Outstanding 2.24M shares +109%
Entity Public Float 21M USD -8.7%
Common Stock, Value, Issued 0 USD
Weighted Average Number of Shares Outstanding, Basic 1.9K shares +78.2%
Weighted Average Number of Shares Outstanding, Diluted 1.9K shares +78.2%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 16M USD +17.2%
Operating Income (Loss) -31.5M USD +26.2%
Nonoperating Income (Expense) 1.39M USD -43.4%
Net Income (Loss) Attributable to Parent -30.1M USD +25.1%
Earnings Per Share, Basic -15.9 USD/shares +58%
Earnings Per Share, Diluted -15.9 USD/shares +58%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 4.99M USD -61%
Marketable Securities, Current 7.14M USD +24.8%
Cash, Cash Equivalents, and Short-term Investments 20.8M USD
Other Assets, Current 214K USD -72.7%
Assets, Current 6.41M USD -56.5%
Property, Plant and Equipment, Net 0 USD -100%
Operating Lease, Right-of-Use Asset 0 USD -100%
Other Assets, Noncurrent 1.6M USD +37.7%
Assets 8.01M USD -56.1%
Accounts Payable, Current 2.03M USD -18.7%
Accrued Liabilities, Current 3.24M USD +84.8%
Liabilities, Current 5.28M USD -5.78%
Operating Lease, Liability, Noncurrent 0 USD -100%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 5.28M USD -24.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax 119K USD +1388%
Retained Earnings (Accumulated Deficit) -189M USD -18.9%
Stockholders' Equity Attributable to Parent 2.72M USD -75.7%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 2.5B USD
Liabilities and Equity 8.01M USD -56.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.74M USD +40.9%
Net Cash Provided by (Used in) Financing Activities 5K USD +66.7%
Net Cash Provided by (Used in) Investing Activities 0 USD -100%
Common Stock, Shares Authorized 120M shares 0%
Common Stock, Shares, Issued 2.24M shares +109%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -7.66M USD -6.8%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 5.07M USD -60.6%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD
Deferred Tax Assets, Valuation Allowance 41M USD +8.49%
Deferred Tax Assets, Gross 41M USD +7%
Operating Lease, Liability 1.64M USD -40.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -30M USD +25.3%
Lessee, Operating Lease, Liability, to be Paid 3.04M USD
Property, Plant and Equipment, Gross 0 USD -100%
Operating Lease, Liability, Current 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.37M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 1.32M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 90K USD -66.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 28K USD
Deferred Tax Assets, Operating Loss Carryforwards 19.4M USD +25.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 30M shares 0%
Unrecognized Tax Benefits 1.54M USD +24.4%
Operating Lease, Payments 1.32M USD +3.94%
Additional Paid in Capital 192M USD +12.6%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 13K USD 0%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 3.47M USD -2.53%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%